Eradication of spontaneous malignancy by local immunotherapy

Science Translational Medicine

Volumn 10, Issue 426, 2018, Pages

  Sagiv Barfi, Idit ^a   Czerwinski, Debra K ^a   Levy, Shoshana ^a   Alam, Israt S ^a   Mayer, Aaron T ^a   Gambhir, Sanjiv S ^a   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSTIMULATING AGENT; OLIGODEOXYNUCLEOTIDE; OX40 LIGAND; OX40 MONOCLONAL ANTIBODY; RESIQUIMOD; SD 101; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR 9 LIGAND; UNCLASSIFIED DRUG; ANTIBODY; DIFFERENTIATION ANTIGEN; OX40IG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; COLON CANCER; CONTROLLED STUDY; CPG ISLAND; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LOW DRUG DOSE; LYMPHOCYTE FUNCTION; LYMPHOMA; MALIGNANT NEOPLASM; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; ANIMAL; DISEASE MODEL; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASM; PROCEDURES; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES; ANTIGENS, DIFFERENTIATION; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOTHERAPY; MICE; MICE, TRANSGENIC; NEOPLASMS; TOLL-LIKE RECEPTOR 9;

EID: 85041668143     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aan4488     Document Type: Article

References (43)

1. + T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 5, 780-787 (1999).
2. K. Staveley-O’Carroll, E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, H. Levitsky, Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc. Natl. Acad. Sci. U.S.A. 95, 1178-1183 (1998).
3. + T cells. J. Immunol. 179, 1427-1430 (2007).
4. + Tregs. Blood 110, 2501-2510 (2007).
5. J. D. Fontenot, J. P. Rasmussen, L. M. Williams, J. L. Dooley, A. G. Farr, A. Y. Rudensky, Regulatory T cell lineage specification by the forkhead transcription factor Foxp3. Immunity 22, 329-341 (2005).
6. E. Y. Lin, J. G. Jones, P. Li, L. Zhu, K. D. Whitney, W. J. Muller, J. W. Pollard, Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am. J. Pathol. 163, 2113-2126 (2003).
7. C. T. Guy, R. D. Cardiff, W. J. Muller, Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12, 954-961 (1992).
8. T. Yamaguchi, K. Hirota, K. Nagahama, K. Ohkawa, T. Takahashi, T. Nomura, S. Sakaguchi, Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 27, 145-159 (2007).
9. + Tregs using the DEREG mouse model. Methods Mol. Biol. 707, 157-172 (2011).
10. + regulatory T cells induces a scurfy-like disease. J. Exp. Med. 204, 57-63 (2007).
11. K. S. Voo, L. Bover, M. L. Harline, L. T. Vien, V. Facchinetti, K. Arima, L. W. Kwak, Y. J. Liu, Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function. J. Immunol. 191, 3641-3650 (2013).
12. Y. Bulliard, R. Jolicoeur, J. Zhang, G. Dranoff, N. S. Wilson, J. L. Brogdon, OX40 engagement depletes intratumoral Tregs via activating FcRs, leading to antitumor efficacy. Immunol. Cell Biol. 92, 475-480 (2014).
13. F. Nimmerjahn, J. V. Ravetch, Fc receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34-47 (2008).
14. F. Li, J. V. Ravetch, Inhibitory Fc receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333, 1030-1034 (2011).
15. D. Zhang, M. V. Goldberg, M. L. Chiu, Fc engineering approaches to enhance the agonism and effector functions of an anti-OX40 antibody. J. Biol. Chem. 291, 27134-27146 (2016).
16. P. O. Krutzik, G. P. Nolan, Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling. Nat. Methods 3, 361-368 (2006).
17. A. Burocchi, P. Pittoni, A. Gorzanelli, M. P. Colombo, S. Piconese, Intratumor OX40 stimulation inhibits IRF1 expression and IL-10 production by Treg cells while enhancing CD40L expression by effector memory T cells. Eur. J. Immunol. 41, 3615-3626 (2011).
18. A. P. Vicari, C. Chiodoni, C. Vaure, S. Ait-Yahia, C. Dercamp, F. Matsos, O. Reynard, C. Taverne, P. Merle, M. P. Colombo, A. O’Garra, G. Trinchieri, C. Caux, Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med. 196, 541-549 (2002).
19. C. Guiducci, A. P. Vicari, S. Sangaletti, G. Trinchieri, M. P. Colombo, Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65, 3437-3446 (2005).
20. S. N. Gettinger, L. Horn, L. Gandhi, D. R. Spigel, S. J. Antonia, N. A. Rizvi, J. D. Powderly, R. S. Heist, R. D. Carvajal, D. M. Jackman, L. V. Sequist, D. C. Smith, P. Leming, D. P. Carbone, M. C. Pinder-Schenck, S. L. Topalian, F. S. Hodi, J. A. Sosman, M. Sznol, D. F. McDermott, D. M. Pardoll, V. Sankar, C. M. Ahlers, M. Salvati, J. M. Wigginton, M. D. Hellmann, G. D. Kollia, A. K. Gupta, J. R. Brahmer, Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 33, 2004-2012 (2015).
21. D. F. McDermott, C. G. Drake, M. Sznol, T. K. Choueiri, J. D. Powderly, D. C. Smith, J. R. Brahmer, R. D. Carvajal, H. J. Hammers, I. Puzanov, F. S. Hodi, H. M. Kluger, S. L. Topalian, D. M. Pardoll, J. M. Wigginton, G. D. Kollia, A. Gupta, D. McDonald, V. Sankar, J. A. Sosman, M. B. Atkins, Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J. Clin. Oncol. 33, 2013-2020 (2015).
22. E. Gonzalez-Rodriguez, D. Rodriguez-Abreu; Spanish Group for Cancer Immuno-Biotherapy, Immune checkpoint inhibitors: Review and management of endocrine adverse events. Oncologist 21, 804-816 (2016).
23. L. Kottschade, A. Brys, T. Peikert, M. Ryder, L. Raffals, J. Brewer, P. Mosca, S. Markovic; Midwest Melanoma Partnership, A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. Melanoma Res. 26, 469-480 (2016).
24. A. Sgambato, F. Casaluce, P. C. Sacco, G. Palazzolo, P. Maione, A. Rossi, F. Ciardiello, C. Gridelli, Anti PD-1 and PDL-1 immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC): A review on toxicity profile and its management. Curr. Drug Saf. 11, 62-68 (2016).
25. + T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin. Cancer Res. 19, 5381-5389 (2013).
26. A. Marabelle, H. Kohrt, R. Levy, Intratumoral anti-CTLA-4 therapy: Enhancing efficacy while avoiding toxicity. Clin. Cancer Res. 19, 5261-5263 (2013).
27. A. Marabelle, H. Kohrt, I. Sagiv-Barfi, B. Ajami, R. C. Axtell, G. Zhou, R. Rajapaksa, M. R. Green, J. Torchia, J. Brody, R. Luong, M. D. Rosenblum, L. Steinman, H. I. Levitsky, V. Tse, R. Levy, Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J. Clin. Invest. 123, 2447-2463 (2013).
28. S. Piconese, B. Valzasina, M. P. Colombo, OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J. Exp. Med. 205, 825-839 (2008).
29. J. Ziai, G. Frantz, L. Zhang, C. Kozlowski, H. Gilbert, J. Smith, M. Kowanetz, J. M. Kim, M. Huseni, Prevalence analysis of OX40-positive cell populations in solid tumors. J. Immunother. Cancer 3 (suppl. 2), P113 (2015).
30. S. Mallett, S. Fossum, A. N. Barclay, Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes-A molecule related to nerve growth factor receptor. EMBO J. 9, 1063-1068 (1990).
31. K. Sugamura, N. Ishii, A. D. Weinberg, Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat. Rev. Immunol. 4, 420-431 (2004).
32. T. A. Triplett, C. G. Tucker, K. C. Triplett, Z. Alderman, L. Sun, L. E. Ling, E. T. Akporiaye, A. D. Weinberg, STAT3 signaling is required for optimal regression of large established tumors in mice treated with anti-OX40 and TGF receptor blockade. Cancer Immunol. Res. 3, 526-535 (2015).
33. K. A. Murphy, M. G. Lechner, F. E. Popescu, J. Bedi, S. A. Decker, P. Hu, J. R. Erickson, M. G. O’Sullivan, L. Swier, A. M. Salazar, M. R. Olin, A. L. Epstein, J. R. Ohlfest, An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas. Clin. Cancer Res. 18, 4657-4668 (2012).
34. + T cell tolerance to an endogenous tumor antigen. J. Immunol. 176, 974-983 (2006).
35. A. Curti, M. Parenza, M. P. Colombo, Autologous and MHC class I-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphoma. Blood 101, 568-575 (2003).
36. A. Song, J. Song, X. Tang, M. Croft, Cooperation between CD4 and CD8 T cells for anti-tumor activity is enhanced by OX40 signals. Eur. J. Immunol. 37, 1224-1232 (2007).
37. + T cells is associated with concomitant memory and terminally differentiated phenotype. J. Exp. Med. 209, 2113-2126 (2012).
38. M. J. Gough, C. E. Ruby, W. L. Redmond, B. Dhungel, A. Brown, A. D. Weinberg, OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res. 68, 5206-5215 (2008).
39. + regulatory T cell-mediated suppression of antitumor immunity. Int. J. Cancer 125, 630-638 (2009).
40. + T cells blocks their inhibitory activity: A novel regulatory role for OX40 and its comparison with GITR. Blood 105, 2845-2851 (2005).
41. R. G. Lapidus, S. J. Nass, N. E. Davidson, The loss of estrogen and progesterone receptor gene expression in human breast cancer. J. Mammary Gland Biol. Neoplasia 3, 85-94 (1998).
42. S. Ménard, E. Tagliabue, M. Campiglio, S. M. Pupa, Role of HER2 gene overexpression in breast carcinoma. J. Cell. Physiol. 182, 150-162 (2000).
43. J. E. Maglione, D. Moghanaki, L. J. T. Young, C. K. Manner, L. G. Ellies, S. O. Joseph, B. Nicholson, R. D. Cardiff, C. L. MacLeod, Transgenic Polyoma middle-T mice model premalignant mammary disease. Cancer Res. 61, 8298-8305 (2001).